Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas.
Esteban-Burgos L., Wang H., Nieto P., Zheng J., Blanco-Aparicio C., Varela C., Gómez-López G., Fernández-García F., Sanclemente M., Guerra C. et al., 2020/09/29. Proceedings of the National Academy of Sciences of the United States of America, 117 (39) pp. 24415-24426. Peer-reviewed.
ici le détail